How Does Sobi Stack Up After Its 14.5% Slide and Recent FDA Approval?

If you are wondering what to do with your Swedish Orphan Biovitrum shares, or considering adding them to your watchlist, you are not alone. The stock has sparked plenty of conversation among investors, especially after a rollercoaster 12 months. Year-to-date, the share price is down 14.5%, and it has slipped 13.6% over the past year. Short-term traders saw some mild volatility too, with a dip of 2.5% in the past week serving as a reality check after a 1.2% bump over the last month.

However, the longer-term performance tells a different story. The stock has achieved nearly 29% gains over three years and climbed 32.7% over five years. These returns stand out in a market filled with pharma sector ups and downs and suggest that changes in risk perception may have opened up new opportunities for long-term investors.

If you are curious about how Swedish Orphan Biovitrum stacks up on valuation, most metric checks indicate it looks very compelling. The company scores a strong 5 out of 6 on our valuation checklist, indicating it screens as undervalued across nearly every measure. With market sentiment shifting and a valuation setup this attractive, now is an ideal time to break down exactly where the value lies. Up next, we will look at these valuation checks in detail before exploring an even more insightful way to assess the company’s true worth.

Why Swedish Orphan Biovitrum is lagging behind its peers

Approach 1: Swedish Orphan Biovitrum Discounted Cash Flow (DCF) Analysis

The Discounted Cash Flow (DCF) model estimates a company's intrinsic value by projecting its future cash flows and discounting them back to today, adjusting for the time value of money. For Swedish Orphan Biovitrum, we look at the Free Cash Flow (FCF) generated and anticipated over the next decade, all measured in SEK.

Currently, Swedish Orphan Biovitrum generates SEK 3.05 billion in FCF. Analyst estimates expect a strong trajectory over the next few years, projecting around SEK 8.22 billion in 2026 and peaking at SEK 10.22 billion by 2028. After that, using reasonable assumptions beyond the analysts' direct estimates, cash flows are expected to stabilize and then gradually decline, with SEK 7.30 billion forecasted for 2034 and SEK 7.29 billion in 2035. These projections help shape a comprehensive outlook for investors and provide insights into long-term value creation.

The resulting DCF calculation produces an intrinsic value of SEK 559.42 per share. This is a substantial 50.7% higher than the stock’s current market price. This suggests a significant margin of safety and indicates the market may not yet reflect the company’s underlying value.

Result: UNDERVALUED

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Swedish Orphan Biovitrum.

Our Discounted Cash Flow (DCF) analysis suggests Swedish Orphan Biovitrum is undervalued by 50.7%. Track this in your watchlist or portfolio, or discover more undervalued stocks.

Approach 2: Swedish Orphan Biovitrum Price vs Earnings

For companies like Swedish Orphan Biovitrum that generate consistent profits, the Price-to-Earnings (PE) ratio remains one of the most relevant valuation tools. The PE ratio helps investors gauge how much they are paying for a company’s earnings. This makes it especially useful for established, profitable pharmaceutical businesses.

Determining what qualifies as a "normal" or "fair" PE ratio depends on several factors, including expected earnings growth and perceived risks. Higher growth usually justifies a higher PE ratio, while increased risk or slower growth would warrant a lower one. Presently, Swedish Orphan Biovitrum trades on a PE ratio of 21.94x. For context, the average PE for the broader Biotechs industry is 30.29x. Its direct peers are priced much higher at an average of 60.74x.

However, comparisons to simple averages can be misleading. This is where Simply Wall St’s proprietary “Fair Ratio” comes in, offering a more nuanced benchmark. The Fair Ratio, calculated at 46.88x, considers a blend of the company’s growth outlook, risk profile, profit margins, industry dynamics, and market cap. This approach adds context and goes beyond headline multiples to capture the full investment picture.

With Swedish Orphan Biovitrum’s actual PE ratio of 21.94x sitting well below the Fair Ratio of 46.88x, the stock looks attractively valued on an earnings basis.

Result: UNDERVALUED

PE ratios tell one story, but what if the real opportunity lies elsewhere? Discover companies where insiders are betting big on explosive growth.

Upgrade Your Decision Making: Choose your Swedish Orphan Biovitrum Narrative

Earlier we mentioned that there is an even better way to understand valuation, so let’s introduce you to Narratives. A Narrative is a personal story or viewpoint that connects your expectations for a company’s future, such as revenue, earnings, margins, and fair value, to a financial forecast. This approach brings the numbers to life with a real-world outlook.

Narratives go beyond static metrics; they empower you to make smarter investment decisions by linking a company’s story directly to a fair value. This allows you to see exactly how your perspective translates into buy or sell signals. You can easily create or explore Narratives for Swedish Orphan Biovitrum within the Simply Wall St Community page. Millions of investors already use this tool to refine their strategies.

What makes Narratives especially powerful is that they update automatically when fresh information such as news or earnings is released, ensuring your view stays relevant without extra effort. For example, an optimistic investor might project SEK 9.3 billion in earnings and a fair value of SEK 380.0 per share, while a more cautious view forecasts SEK 5.2 billion and SEK 275.0. This approach lets you compare your assumptions against the market and the wider community at a glance.

Do you think there's more to the story for Swedish Orphan Biovitrum? Create your own Narrative to let the Community know!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com